Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Enveric Biosciences Inc (ENVB) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance

Enveric Biosciences IncTrade
Health Care Select Sector SPDR FundTrade

Price performance (Past 24H)

Key statistics

Enveric Biosciences Inc vs Health Care Select Sector SPDR Fund — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Health Care Select Sector SPDR Fund trades at $167.91. The key difference: Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.

ENVBXLV
Market Cap
$6.20M
Sector
Health
52-Week High
$17.40$168.44
52-Week Low
$1.27$131.16
Enterprise Value
$1.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Enveric Biosciences Inc

ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.

Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.

Health Care Select Sector SPDR Fund

XLV trades at $165.68, up 0.75% with a bullish technical signal from moving averages. The healthcare ETF shows strong defensive positioning amid market volatility, with recent articles highlighting its cost efficiency at 0.08% expense ratio and $41.7 billion AUM. Technical indicators show support at $164 and resistance at $167, with RSI levels in neutral territory suggesting balanced momentum.

The outlook remains positive given healthcare's defensive characteristics and recent sector inflows. Key risks include regulatory pressures and competitive ETF offerings, but XLV's diversification across 60 healthcare stocks provides stability. Analyst comparisons favor XLV for lower costs and steady performance versus specialized biotech ETFs.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Enveric Biosciences Inc

Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.

Read more on ENVB

About Health Care Select Sector SPDR Fund

In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.

Read more on XLV